Allianz Asset Management GmbH Has $1.30 Million Stake in USANA Health Sciences, Inc. $USNA

Allianz Asset Management GmbH raised its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 126.0% in the third quarter, HoldingsChannel.com reports. The firm owned 47,203 shares of the company’s stock after buying an additional 26,314 shares during the period. Allianz Asset Management GmbH’s holdings in USANA Health Sciences were worth $1,300,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in USNA. Tower Research Capital LLC TRC grew its holdings in shares of USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after buying an additional 1,901 shares during the last quarter. CWM LLC raised its holdings in shares of USANA Health Sciences by 109.7% in the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock worth $84,000 after acquiring an additional 1,445 shares during the last quarter. Quantbot Technologies LP increased its holdings in USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after purchasing an additional 646 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of USANA Health Sciences in the second quarter worth approximately $202,000. Finally, Intech Investment Management LLC bought a new position in shares of USANA Health Sciences in the second quarter valued at approximately $208,000. 54.25% of the stock is owned by institutional investors.

USANA Health Sciences Stock Performance

NYSE:USNA opened at $20.95 on Friday. The business’s fifty day moving average is $20.68 and its 200 day moving average is $23.84. The firm has a market cap of $382.97 million, a price-to-earnings ratio of 23.81, a PEG ratio of 0.90 and a beta of 0.67. USANA Health Sciences, Inc. has a 52-week low of $18.48 and a 52-week high of $38.32.

Analysts Set New Price Targets

A number of research firms recently weighed in on USNA. Zacks Research lowered shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat, USANA Health Sciences presently has an average rating of “Reduce” and a consensus price target of $36.00.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.